Targeted Cancer Therapies Underused Due to Cost, Access Barriers

The New York Times reports that targeted gene therapies for cancer are highly effective but underutilized due to high costs, slow adoption, and the sheer number of available treatments. The article highlights systemic barriers in healthcare delivery that limit patient access, though specific data or policy proposals are not detailed. This matters because it underscores a gap between medical innovation and real-world patient outcomes, potentially influencing healthcare policy and pharmaceutical pricing debates.